PPT-No randomisation

N 100 W12 W24 Arm B compensated cirrhosis N 31 N 29 Arm C compensated cirrhosis Arm A No cirrhosis AGATEII Study OBVPTVr RBV in genotype 4 Egyptian patients without or with cirrhosis . Standard Operating Procedure 9 Randomisation and Blinding Page 1 of 9 Effective: 6 August 2012 Version 1.3 Randomisation and Blinding Version 1. 3 Effective date: 6 August 2012 Author: Claire Daffe PGDip. MRCGP. GP and Clinical Lecturer. Honorary Fellow at The Centre for Evidence Based Medicine. University of Oxford . R. andomised. . controlled trials. PEBM. 2013. Warm up quiz…... Apple . inc.. UKMF Spring Day. Assessment of disease response, CR and beyond. .. Roger Owen. St James’s Institute of Oncology. Leeds, UK. Myeloma trials: the challenges. What do we need?. Flow . cytometry. in MM.. Double - blind 90% Power N=324 Study Design: Dose Ranging Phase 2b 6 months follow Chloroquine # + 15mg Primaquine + Days 2 - 15 (n=54) Chloroquine # Days 1 - 3 (n=54) Chloroquine # + 300mg Tafe Carl Hamblyn. SO_P. S_AR. Designing an Experiment. An experiment is a set of observations made under conditioned controlled by the observer. Experiments allow us to claim cause and effect (if correctly designed). *. 1:1. Open-label. ≥ 18 years. HCV genotype 4. HCV RNA ≥ 1 000 IU/mL. Naïve or pre-treated with PEG-IFN + RBV Compensated cirrhosis ** . No HBV or HIV co-infection. N = 59. W12. OPV/PTV/r + RBV. randomised. controlled N-of 1 trials in patients who have discontinued or are considering discontinuing statin use due to muscle-related symptoms to assess if atorvastatin treatment causes more muscle symptoms than placebo. Open-label. 18-70 years. HCV genotype 1. Naïve or null-response . to PEG-IFN + RBV. HCV RNA > 10 000 IU. /ml. No HBV or HIV coinfection. Design. N = 34. W8. Objective. SVR. 12. (HCV RNA < . 25 IU. Open-label. 18-70 . years. HCV genotype 1. Naïve or null-response . to PEG-IFN + RBV. HCV RNA > 10,000 IU/ml. No cirrhosis . No . HBV or . HIV . co-infection. Design. N = . 39. W12. N = . 40. O. bjective. ≥ 18 years. HCV genotype 3. Treatment-naïve . HCV RNA > 1 000 IU/mL. No cirrhosis **. No HBV co-infection. No HIV co-infection. ENDURANCE-3 Study: . glecaprevir. /. pibrentasvir. . vs SOF DCV in genotype 3 without cirrhosis. A-899-0059-12977. Presented by Professor Sarah Fidler . on behalf of the RIVER study team and investigators. Disclosures . MSD . donated drugs (. Raltegravir. and Vorinostat) and GSK contributed some of its intellectual property to the study through an industry academic partnership. Childhood. Orla Doyle . (. UCD School of Economics & UCD Geary Institute). Conference . on Irish Economic Policy. 1. st. February 2013. Importance of Early Childhood Investment. Targeted early intervention programmes effective way of reducing socio-economic inequalities in children’s skills . the RECOVERY trial. Second Randomisation. IL-6 and . Tocilizumab. IL-6. binds surface receptor. IL-6. binds soluble receptor. IL-6/IL-6R complex binds gp130 on cell surface. IL-6/IL-6R/gp130 complex activates JAK1/2-STAT1/3 signalling. Adrian Boyle. Suturing versus conservative management of lacerations of the hand: randomised controlled trial. BMJ. What did they do? PICO. Population. Consecutive (11am-11pm) patients with hand lacerations less than 2cm long.